### Givlaari (givosiran)
**Effective 08/01/2021**

<table>
<thead>
<tr>
<th>Plan</th>
<th>Program Type</th>
<th>Benefit</th>
<th>Specialty Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>☑️ MassHealth</td>
<td>☑️ Prior Authorization</td>
<td>☐️ Pharmacy Benefit</td>
<td>N/A</td>
</tr>
<tr>
<td>☑️ Commercial/Exchange</td>
<td>☑️ Quantity Limit</td>
<td>☑️ Medical Benefit (NLX)</td>
<td></td>
</tr>
<tr>
<td>☑️ MassHealth</td>
<td>☑️ Step Therapy</td>
<td>☑️ Commercial Benefit</td>
<td></td>
</tr>
<tr>
<td>☑️ Commercial/Exchange</td>
<td>☑️ Step Therapy</td>
<td>☑️ Exchange Benefit</td>
<td></td>
</tr>
</tbody>
</table>

#### Specialty Medications
- **All Plans**
  - Phone: 866-814-5506
  - Fax: 866-249-6155

#### Non-Specialty Medications
- **MassHealth**
  - Phone: 877-433-7643
  - Fax: 866-255-7569

- **Commercial**
  - Phone: 800-294-5979
  - Fax: 888-836-0730

- **Exchange**
  - Phone: 855-582-2022
  - Fax: 855-245-2134

#### Medical Specialty Medications (NLX)
- **All Plans**
  - Phone: 844-345-2803
  - Fax: 844-851-0882

#### Contact Information
**Overview**
Givosiran is an aminolevulinate synthase 1-directed small interfering RNA indicated for the treatment of adults with acute hepatic porphyria (AHPs).

**Coverage Guidelines**
Authorization may be granted for members who are currently receiving treatment with Givlaari, excluding when the product is obtained as samples or via manufacturer’s patient assistance program or

Approval of Givlaari will be granted if the member meets all following criteria and documentation has been submitted:
1. The member has a diagnosis of acute hepatic porphyria
2. The member is ≥ 18 years of age
3. Member’s current weight (use to verify correct dosing; may take this information over the phone if missing on PA request)
4. Appropriate dosing

**Continuation of Therapy**
Reauthorization of Givlaari may be granted when ALL the following is met:
1. The member has experienced a positive clinical response as evidenced by ALL of the following:
2. Updated member weight (use to verify correct dosing; may take this information over the phone if missing on PA request)

**Limitations**
Initial approvals and reauthorizations will be granted for 12 months.
References

1. Givlaari (givosiran) [prescribing information]. Cambridge, MA: Alnylam Pharmaceuticals; November 2019

Review History

05/19/2021: Reviewed and Updated May P&T Meeting to meet MH UPPL for 7/1/2021; updated duration of approval. Effective 08/01/2021.

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.